| International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data DA Arber, A Orazi, RP Hasserjian, MJ Borowitz, KR Calvo, HM Kvasnicka, ... Blood, The Journal of the American Society of Hematology 140 (11), 1200-1228, 2022 | 1224 | 2022 |
| Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study AH Wei, SA Strickland Jr, JZ Hou, W Fiedler, TL Lin, RB Walter, A Enjeti, ... Journal of Clinical Oncology 37 (15), 1277-1284, 2019 | 644 | 2019 |
| Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes E Bernard, Y Nannya, RP Hasserjian, SM Devlin, H Tuechler, ... Nature medicine 26 (10), 1549-1556, 2020 | 476 | 2020 |
| Luspatercept in patients with lower-risk myelodysplastic syndromes P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ... New England Journal of Medicine 382 (2), 140-151, 2020 | 461 | 2020 |
| Molecular international prognostic scoring system for myelodysplastic syndromes E Bernard, H Tuechler, PL Greenberg, RP Hasserjian, JE Arango Ossa, ... NEJM evidence 1 (7), EVIDoa2200008, 2022 | 428 | 2022 |
| The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia EM Stein, G Garcia-Manero, DA Rizzieri, R Tibes, JG Berdeja, ... Blood, The Journal of the American Society of Hematology 131 (24), 2661-2669, 2018 | 381 | 2018 |
| HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs CC Carter, A Onafuwa-Nuga, LA McNamara, J Riddell IV, D Bixby, ... Nature medicine 16 (4), 446-451, 2010 | 356 | 2010 |
| Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia S Pei, DA Pollyea, A Gustafson, BM Stevens, M Minhajuddin, R Fu, ... Cancer discovery 10 (4), 536-551, 2020 | 327 | 2020 |
| A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia HE Ramsey, MA Fischer, T Lee, AE Gorska, MP Arrate, L Fuller, KL Boyd, ... Cancer discovery 8 (12), 1566-1581, 2018 | 303 | 2018 |
| SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS L Malcovati, K Stevenson, E Papaemmanuil, D Neuberg, R Bejar, ... Blood, The Journal of the American Society of Hematology 136 (2), 157-170, 2020 | 248 | 2020 |
| Getting to the stem of chronic myeloid leukaemia M Savona, M Talpaz Nature Reviews Cancer 8 (5), 341-350, 2008 | 248 | 2008 |
| Synseg-net: Synthetic segmentation without target modality ground truth Y Huo, Z Xu, H Moon, S Bao, A Assad, TK Moyo, MR Savona, ... IEEE transactions on medical imaging 38 (4), 1016-1025, 2018 | 242 | 2018 |
| TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups D Haase, KE Stevenson, D Neuberg, JP Maciejewski, A Nazha, ... Leukemia 33 (7), 1747-1758, 2019 | 225 | 2019 |
| Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first … HA Burris, IW Flinn, MR Patel, TS Fenske, C Deng, DM Brander, ... The Lancet Oncology 19 (4), 486-496, 2018 | 218 | 2018 |
| Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML RT Swords, S Coutre, MB Maris, JF Zeidner, JM Foran, J Cruz, HP Erba, ... Blood, The Journal of the American Society of Hematology 131 (13), 1415-1424, 2018 | 192 | 2018 |
| Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells BM Stevens, CL Jones, DA Pollyea, R Culp-Hill, A D’Alessandro, ... Nature cancer 1 (12), 1176-1187, 2020 | 188 | 2020 |
| An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults MR Savona, L Malcovati, R Komrokji, RV Tiu, TI Mughal, A Orazi, ... Blood, The Journal of the American Society of Hematology 125 (12), 1857-1865, 2015 | 186 | 2015 |
| Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study G Garcia-Manero, EA Griffiths, DP Steensma, GJ Roboz, R Wells, ... Blood, The Journal of the American Society of Hematology 136 (6), 674-683, 2020 | 178 | 2020 |
| Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study EM Stein, CD DiNardo, AT Fathi, AS Mims, KW Pratz, MR Savona, ... Blood, The Journal of the American Society of Hematology 137 (13), 1792-1803, 2021 | 172 | 2021 |
| Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial HM Kantarjian, GJ Roboz, PL Kropf, KWL Yee, CL O'Connell, R Tibes, ... The Lancet Oncology 18 (10), 1317-1326, 2017 | 170 | 2017 |
